The JAK2 V617F mouse survival assessment experiment is a specialized preclinical study designed to evaluate overall survival, disease progression, and therapeutic efficacy in murine models carrying the human JAK2 V617F driver mutation. This experiment delivers critical efficacy and pharmacodynamic evidence for the development of targeted therapies against myeloproliferative neoplasms (MPNs), including polycythemia vera, essential thrombocythemia, and primary myelofibrosis. By integrating longitudinal Kaplan-Meier survival analysis with hematological, pathological, and molecular endpoints, the platform enables robust, statistically powered conclusions about treatment benefit.
Technical Overview
The JAK2 V617F mutation is a somatic gain-of-function substitution (valine to phenylalanine at codon 617) in the pseudokinase domain of the Janus kinase 2 gene. It is the most prevalent driver mutation in BCR-ABL-negative myeloproliferative neoplasms, present in more than 95% of polycythemia vera patients and approximately 50-60% of essential thrombocythemia and primary myelofibrosis cases. The mutation disrupts autoinhibitory regulation of JAK2, producing constitutive JAK-STAT signaling, hypersensitive cytokine responses, and uncontrolled myeloproliferation.
Murine models engineered to express human JAK2 V617F in the hematopoietic compartment faithfully recapitulate key features of human MPN, including erythrocytosis, leukocytosis, marked splenomegaly, extramedullary hematopoiesis, and progressive bone marrow fibrosis. The JAK2 V617F mouse survival assessment experiment is therefore a gold-standard in vivo assay for quantifying how genetic background, disease modifiers, or investigational therapies influence disease trajectory and lifespan. Survival serves as the most stringent integrative endpoint, reflecting the cumulative impact of a test article on disease burden, organ pathology, and systemic tolerance.
Testing Samples
Conditional JAK2 V617F Knock-in Mice
Transgenic mice harboring a loxP-flanked wild-type JAK2 exon 12 cassette with a V617F point mutation, activated via Cre recombinase under hematopoietic promoters (Vav-Cre, Mx1-Cre, or Scl-Cre). These mice develop a polycythemia vera-like phenotype and are the primary cohort for long-term survival studies.
Bone Marrow Transplantation Models
Lethally irradiated recipient mice reconstituted with JAK2 V617F-transduced hematopoietic stem cells or bone marrow from diseased donor mice. This syngeneic transplant approach generates synchronized disease onset and is well suited for rapid efficacy screening of JAK inhibitors and combination regimens.
Test Articles
- Small-molecule JAK1/JAK2 inhibitors (e.g., ruxolitinib, fedratinib, pacritinib analogs)
- Novel allosteric or allele-selective JAK2 inhibitors
- HIF-PHI agents and other pathway modulators for polycythemia management
- Biologics, antibody-drug conjugates, antisense oligonucleotides, and mRNA therapeutics
- Combination regimens evaluated for survival additivity or synergy
Longitudinal Biological Specimens
- Serial peripheral blood samples for complete blood counts and flow cytometry
- Spleen, liver, and bone marrow harvested at necropsy or scheduled interim sacrifice
- Plasma and serum for cytokine profiling and pharmacokinetic/pharmacodynamic correlation
Testing Items
- Overall survival (primary endpoint) and median survival time
- Disease-free survival and time-to-progression analysis
- Hematological parameters: erythrocyte count, hemoglobin, hematocrit, leukocyte and platelet counts
- Spleen weight, spleen-to-body-weight ratio, and liver weight indices
- Histopathological grading of splenic extramedullary hematopoiesis and reticulin fibrosis in bone marrow
- Flow cytometric quantification of myeloid and erythroid progenitor compartments
- JAK-STAT pathway activation markers (phospho-STAT3/STAT5) in hematopoietic tissues
- Allele burden and mutant genotype confirmation via qPCR or digital PCR
- Body weight, clinical score, and cage-side observations throughout the observation window
Testing Methods
Study Design and Grouping
Studies are designed with statistical power analysis, typically allocating 10-20 mice per group across vehicle control, positive control (e.g., ruxolitinib), and multiple dose levels of the test article. Randomization and blinding procedures are applied to minimize bias, and sex-balanced cohorts are maintained to capture sex-dependent differences in disease penetrance.
Survival Monitoring and Humane Endpoints
Mice are monitored daily with detailed clinical scoring for body condition, posture, activity, and hydration. Predefined humane endpoints, such as greater than 20% body weight loss, severe lethargy, hind-limb paralysis, or visible abdominal distension from splenomegaly, are applied in accordance with IACUC-approved protocols. Moribund animals are euthanized and recorded as event deaths to ensure ethical compliance without compromising endpoint integrity.
Hematological and Pathological Analysis
Peripheral blood is collected via submandibular or tail vein sampling at baseline and scheduled intervals for complete blood count analysis on a veterinary hematology analyzer. At necropsy, spleen and liver weights are recorded, and fixed tissues are processed for H&E staining, reticulin staining, and blinded pathological scoring by a board-certified veterinary pathologist.
Molecular and Biochemical Analysis
Mutant allele burden is quantified by allele-specific qPCR or droplet digital PCR from peripheral blood or bone marrow genomic DNA. Phospho-flow cytometry and Western blotting of sorted hematopoietic cells assess target engagement, while multiplex cytokine panels quantify inflammatory mediators such as IL-6, TNF-alpha, and G-CSF.
Statistical Analysis
Survival distributions are estimated using the Kaplan-Meier method and compared with the log-rank (Mantel-Cox) test, with hazard ratios calculated via Cox proportional hazards modeling. Continuous endpoints are analyzed by ANOVA or repeated-measures mixed models, and multiplicity is controlled through appropriate post-hoc corrections.
Applications
- Efficacy evaluation of novel JAK2 inhibitors and MPN therapeutics prior to IND-enabling studies
- Comparative survival benchmarking of test articles against standard-of-care JAK inhibitors
- Assessment of fibrosis-modifying agents and anti-stromal therapeutic strategies
- Genetic modifier studies evaluating how background mutations (e.g., TET2, ASXL1, CALR) alter JAK2 V617F disease course and survival
- Pharmacodynamic validation of target engagement linked to survival benefit
- Support for publication-grade preclinical data packages and regulatory submissions
FAQ
What is the typical duration of a JAK2 V617F mouse survival study?
Depending on the model, survival studies typically run from 12 weeks to more than 12 months. Bone marrow transplant models with aggressive disease may reach endpoints within 8-16 weeks, while conditional knock-in models can require 6-12 months for full survival curve resolution.
How many mice are required per group?
Group sizes are determined by power analysis, but 12-20 mice per group are standard for detecting meaningful survival differences with adequate statistical power. Interim satellite groups can be included for pharmacodynamic and histological sampling without reducing survival cohort numbers.
Which positive control compounds are commonly used?
Ruxolitinib is the most frequently used benchmark JAK1/JAK2 inhibitor, with fedratinib and momelotinib serving as comparators depending on the therapeutic hypothesis and indication focus.
Can survival be combined with disease-modifying endpoints?
Yes. The protocol is routinely integrated with serial hematology, allele burden tracking, fibrosis scoring, and imaging, allowing investigators to correlate survival extension with mechanistic evidence of disease modification rather than palliative benefit alone.
How is humane endpoint handling reconciled with survival data integrity?
Moribund mice meeting IACUC-approved criteria are euthanized and censored as event deaths at the date of euthanasia, a widely accepted convention that preserves both animal welfare and the statistical validity of the Kaplan-Meier analysis.